Lincotek Medical04.23.20
Lincotek Medical has made a significant investment in its Chinese manufacturing center in Wuxi, Jiangsu Province. Not only is it doubling its coating capacity for orthopedic implants, but is also introducing a new cleaning and packaging line – designed and built to the highest standards of the medical industry.
The move comes despite the challenges presented by the coronavirus emergency around the world and demonstrates the group’s strength and commitment to the Chinese market.
“Being impacted heavily by the Covid-19 crisis, we are very proud of the fast and professional reaction of our Chinese team,” commented Winfried Schaller, CEO of Lincotek Group. “The manufacturing center has coped well, working alongside local authorities to re-open the plant with additional precautions and regulations in place to protect workers and visitors from the virus, while ensuring a continuous supply of high-quality products reflecting our responsibility as a strategic supplier to the medical industry in China.”
In light of this important responsibility, on April 23, Lincotek Medical announced the expansion of its available services through the doubling of its coating capacity with the installation of a second CAPS Intercooler. This technology is Lincotek proprietary coating equipment, widely recognized in the orthopedic sector for highly advanced porous coatings with unique material performance characteristics and reliable quality. Doubling CAPS capacity will allow the company to satisfy increasing market demand, while maintaining the highest level of service in terms of reactivity and flexibility. This investment will strengthen Lincotek Medical’s ability to offer to customers global risk mitigation capabilities.
With the new investment, the company will be offering to customers cleaning and packaging services for both temporary and final packaging. This represents another step in the integration of new services in the value chain, to provide Chinese and APAC customers simplified supply chain solutions, increased efficiency and reduced lead times.
Mark Huguet, general manager of Lincotek Medical Wuxi said, “In what has been a difficult period, I am very proud, that we are able to announce an important investment in our facility here in China, which will allow us to provide an even higher standard of service and react more quickly to the needs of customers. It shows the level of commitment that Lincotek has to meet the needs of Lincotek Medical’s customer base in China.”
The move comes despite the challenges presented by the coronavirus emergency around the world and demonstrates the group’s strength and commitment to the Chinese market.
“Being impacted heavily by the Covid-19 crisis, we are very proud of the fast and professional reaction of our Chinese team,” commented Winfried Schaller, CEO of Lincotek Group. “The manufacturing center has coped well, working alongside local authorities to re-open the plant with additional precautions and regulations in place to protect workers and visitors from the virus, while ensuring a continuous supply of high-quality products reflecting our responsibility as a strategic supplier to the medical industry in China.”
In light of this important responsibility, on April 23, Lincotek Medical announced the expansion of its available services through the doubling of its coating capacity with the installation of a second CAPS Intercooler. This technology is Lincotek proprietary coating equipment, widely recognized in the orthopedic sector for highly advanced porous coatings with unique material performance characteristics and reliable quality. Doubling CAPS capacity will allow the company to satisfy increasing market demand, while maintaining the highest level of service in terms of reactivity and flexibility. This investment will strengthen Lincotek Medical’s ability to offer to customers global risk mitigation capabilities.
With the new investment, the company will be offering to customers cleaning and packaging services for both temporary and final packaging. This represents another step in the integration of new services in the value chain, to provide Chinese and APAC customers simplified supply chain solutions, increased efficiency and reduced lead times.
Mark Huguet, general manager of Lincotek Medical Wuxi said, “In what has been a difficult period, I am very proud, that we are able to announce an important investment in our facility here in China, which will allow us to provide an even higher standard of service and react more quickly to the needs of customers. It shows the level of commitment that Lincotek has to meet the needs of Lincotek Medical’s customer base in China.”